Mips Logo

Mips

Licenses patented helmet technology to reduce rotational impact injuries in sports and construction.

MIPS | ST

Overview

Corporate Details

ISIN(s):
SE0009216278 (+4 more)
LEI:
549300LZSA4S0L54VQ25
Country:
Sweden
Address:
Kemistvägen 1B, 183 79 TÄBY
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Mips is a developer of helmet-based safety technology focused on reducing head injuries. Its core product is the Mips® Safety System (Multi-Directional Impact Protection System), a patented Brain Protection System (BPS). Born from scientific research by a brain surgeon and a biomechanics scientist, the system incorporates a low-friction layer inside helmets. This layer is designed to move slightly upon an angled impact, helping to redirect harmful rotational motion away from the head and potentially reducing the risk of certain brain injuries. Mips licenses its technology to numerous helmet manufacturers for use in products across a wide range of markets, including cycling, snow sports, motorcycling, equestrian, and construction.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-22 07:30
Quarterly Report
Swedish 2.2 MB
2025-10-22 07:30
Quarterly Report
English 2.2 MB
2025-07-16 07:30
Earnings Release
Swedish 1.9 MB
2025-07-16 07:30
Earnings Release
English 1.9 MB
2025-05-07 11:45
AGM Information
Kommuniké från årsstämman i Mips AB (publ) den 7 maj 2025
Swedish 36.0 KB
2025-05-07 11:45
AGM Information
Press release from the Annual General Meeting in Mips AB (publ) on 7 May 2025
English 33.4 KB
2025-04-24 07:30
Quarterly Report
Swedish 1.2 MB
2025-04-24 07:30
Quarterly Report
English 1.2 MB
2025-03-20 17:20
Annual Report (ESEF)
Swedish 2.5 MB
2025-02-05 18:10
Earnings Release
Mips updates long-term financial target
English 39.4 KB
2025-02-05 18:10
Report Publication Announcement
Mips uppdaterar långsiktigt finansiellt mål
Swedish 39.3 KB
2025-02-05 18:10
Earnings Release
Swedish 3.0 MB
2025-02-05 18:10
Annual Report
English 3.0 MB
2024-10-24 07:30
Quarterly Report
Swedish 1.3 MB
2024-10-24 07:30
Interim / Quarterly Report
English 1.4 MB

Automate Your Workflow. Get a real-time feed of all Mips filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mips

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mips via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-10-25 Thomas Bräutigam Other Sell 4,500 2,430,000.00 SEK
2023-09-14 John Fredrik Kjellberg Other Sell 10,300 3,705,837.00 SEK
2023-03-03 Maria Hedengren Other Buy 200 98,254.00 SEK
2022-10-18 Thomas Bräutigam Other Buy 2,000 609,594.40 SEK
2022-10-17 Thomas Bräutigam Other Buy 3,000 907,927.80 SEK
2022-05-06 Thomas Bräutigam Other Buy 1,000 580,600.00 SEK
2022-05-05 Thomas Bräutigam Other Buy 2,000 1,253,200.00 SEK
2022-03-07 Jonas Rahmn Other Buy 107 75,301.25 SEK
2022-03-07 Jonas Rahmn Other Buy 94 66,317.00 SEK
2022-03-07 Jonas Rahmn Other Buy 90 63,495.00 SEK

Peer Companies

KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America
KZIA
Keros Therapeutics, Inc. Logo
United States of America
KROS
Kura Oncology, Inc. Logo
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
Larimar Therapeutics, Inc. Logo
Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.
United States of America
LRMR
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
LigaChem Biosciences Inc. Logo
Advancing a next-gen ADC platform to develop innovative medicines for unmet needs.
South Korea
141080
Linical Co., Ltd. Logo
Global CRO providing full-service drug development support for biopharma companies.
Japan
2183
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT

Talk to a Data Expert

Have a question? We'll get back to you promptly.